SABCS 2022 | Alliance ACOSOG Z11102: impact of breast conservation therapy on local recurrence in pts with MIBC

Judy Boughey, MD, Mayo Clinic Comprehensive Cancer Center, Rochester, MN, discusses the results from the Phase II ACOSOG Z11102 Alliance (NCT01556243) trial which evaluated the impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral breast cancer (MIBC). The Z11102 clinical trial demonstrates that for women with multiple ipsilateral breast cancer, breast-conserving surgery with adjuvant radiation with lumpectomy site boosts has an acceptably low local recurrence rate (3.2% at 5 years), making this a reasonable consideration for women with 2-3 ipsilateral foci. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.